Castle Biosciences Inc Überblick
Branche: Diagnostics & Research
Sektor: Healthcare
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed wi
Research-Überblick
Letztes Berichtsdatum 2026-07-30Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Castle Biosciences Inc (CSTL): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- CSTL · Nasdaq · MIC XNAS
- Land
- United States
- Handelswährung
- USD
- Branche
- Diagnostics & Research
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-07-30
Primärquellen
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-07-30
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Castle Biosciences Inc für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $103.5M (+20% YoY). Net income/share was $0.16. Net loss was -$16.6M (-22% YoY).
Revenue
$103.5M
+20% YoY
Net income/share
$0.16
reported
Net loss
-$16.6M
-22% YoY
Adjusted EBITDA
$12.4M
reported
Was sich verändert hat
- Revenue +20% YoY to $103.5M.
- Net loss -22% YoY to -$16.6M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.
Earnings release
Bericht öffnen
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
SEC filing
10-Q
Jul 30, 2026
SEC filing
8-K
Jul 30, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 06, 2026
Earnings release
Earnings release
May 06, 2026
SEC filing
10-K
Feb 26, 2026
SEC filing
8-K
Feb 26, 2026
Earnings release
Earnings release
Feb 26, 2026
SEC filing
8-K
Jan 13, 2026
SEC filing
10-Q
Nov 03, 2025
SEC filing
8-K
Nov 03, 2025
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?
Headline from Yahoo Finance: Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Headline from Yahoo Finance: Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know.
Castle Biosciences CCO Tobin W sells $317k in shares
Headline from Investing.com: Castle Biosciences CCO Tobin W sells $317k in shares.
Castle Biosciences CCO Tobin W sells $51,190 in stock
Headline from Investing.com: Castle Biosciences CCO Tobin W sells $51,190 in stock.
Castle Biosciences CCO Tobin W sells $51,190 in stock By Investing.com
Headline from Investing.com UK: Castle Biosciences CCO Tobin W sells $51,190 in stock By Investing.com.
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Headline from Yahoo Finance: Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Gewinn je Aktie
Score 2.00/5
Castle Biosciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Eigenkapitalrendite
Score 2.13/5
Castle Biosciences Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Score 2.02/5
Castle Biosciences Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
0%
10%
20%
30%
40%
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Score 3.73/5
Castle Biosciences Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
0
1
2
3
4
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.
Finanzkennzahlen
Jährlich
Quartalsweise
Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen